NDAINHALATIONPOWDERPriority Review
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Pharmacologic Class:
Prostacycline Vasodilator
Clinical Trials (5)
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Started Apr 2026
344 enrolled
Pulmonary HypertensionInterstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Started Jan 2026
344 enrolled
Pulmonary HypertensionInterstitial Lung Disease
Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension
Started Oct 2025
8 enrolled
Pulmonary Hypertension
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Started Sep 2025
10 enrolled
COPD (Chronic Obstructive Pulmonary Disease)Hypoxemia
A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants
Started Aug 2025
42 enrolled
Healthy Volunteers
Loss of Exclusivity
LOE Date
Feb 3, 2042
193 months away
Patent Expiry
Feb 3, 2042